G
Genprex, Inc.
GNPXCIK 0001595248NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsTexasFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-16.20M
Total Assets
$10.16M
Equity
$7.96M
Shares Out
10.59M
Op. Cash Flow
$-15.31M
Business
Genprex, Inc. is a clinical-stage gene therapy company developing non-viral lipid-nanoparticle and viral-vector therapies for oncology and diabetes. Its lead oncology candidate, REQORSA, delivers the TUSC2 tumor suppressor gene for non-small cell lung cancer and small cell lung cancer in Phase 1/2 trials, often combined with approved therapies. GPX-002, its diabetes candidate using adeno-associated virus vectors, is in preclinical development. The company operates Convergen Biotech as a wholly-owned subsidiary for its diabetes program.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 0 | 6,693 | 15,004 | 25,575 | 22,534 | |
| Research and development | 9 | 11 | 18 | 12 | 9 | |
| General and administrative | 6 | 11 | 13 | 12 | 12 | |
| Total operating expenses | 16 | 21 | 31 | 24 | 21 | |
| Operating loss | −16 | −21 | −31 | −24 | −21 | |
| Other income | 26,900 | 63,574 | — | — | — | |
| Other financing costs | −739,935 | 0 | — | — | — | |
| Realized and unrealized loss | −299 | −570 | −18,676 | — | — | |
| Net loss | −16 | −21 | −31 | −24 | −21 | |
| Deemed dividend related to warrant modification | 0 | −277,119 | 0 | — | — | |
| Net loss attributable to common stockholders | −16 | −21 | −31 | — | — | |
| Net loss per share applicable to common stockholders basic and diluted (in dollars per share) | −17.4 | −266.89 | −22.56 | −19.8 | −0.44 | |
| Weighted average number of common shares basic and diluted (in shares) | 932,730 | 80,139 | 1 | 1 | 47 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-09-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 8 | 2 | 7 | 21 | — | |
| Prepaid expenses and other | 525,928 | 475,807 | 794,138 | 484,224 | — | |
| Total current assets | 8 | 2 | 8 | 21 | — | |
| Property and equipment, net | 0 | 0 | 7,859 | 23,032 | — | |
| Research and development supplies | 2 | 2 | 2 | 3 | — | |
| Total non-current assets | 2 | 2 | 3 | 4 | — | |
| Total assets | 10 | 4 | 11 | 25 | 30 | |
| Accounts payables | 743,070 | 1 | 1 | 442,925 | — | |
| Other current liabilities | 1 | 1 | 2 | 2 | — | |
| Total current liabilities | 2 | 3 | 3 | 3 | — | |
| Derivative liabilities | 22,500 | 0 | — | — | — | |
| Total liabilities | 2 | 3 | — | — | — | |
| Commitments and contingencies (Note 7) | — | — | — | — | — | |
| Preferred stock $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 0 | 0 | 0 | — | — | |
| Common stock $0.001 par value: 200,000,000 shares authorized; 3,291,488 and 217,234 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 3,291 | 217 | 1,486 | 1,203 | 48,020 | |
| Additional paid-in capital | 179 | 156 | 141 | 125 | 124 | |
| Accumulated deficit | −171 | −155 | −134 | −103 | −96 | |
| Total stockholders' equity | 8 | 2 | 7 | 22 | 27 | |
| Total liabilities and stockholders' equity | 10 | 4 | 11 | 25 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Prepaid expenses and other | −50,120 | 328,330 | −298,096 | 27,125 | −126,795 | |
| Research and development supplies | 244,630 | 300,630 | 517,449 | 157,465 | — | |
| Accounts payable | −331,226 | −323,315 | 954,686 | −530,269 | 780,226 | |
| Other current liabilities | 1,690 | −426,723 | −510,765 | 2 | 354,344 | |
| Net cash used in operating activities | −15 | −18 | −25 | −18 | −14 | |
| Disposals of property and equipment | 0 | 1,166 | 169 | 0 | — | |
| Reductions to intellectual property | 0 | 773,478 | — | — | — | |
| Net cash provided by investing activities | 0 | 774,644 | −71,214 | −59,735 | −83,796 | |
| Net proceeds from issuances of common stock | 22 | 12 | 11 | 6,426 | 26 | |
| Net cash provided by financing activities | 22 | 12 | 11 | 6,426 | 26 | |
| Net increase (decrease) in cash and cash equivalents | 6 | −5 | −14 | −18 | 11 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Genprex, Inc.'s CIK number?
Genprex, Inc.'s SEC CIK number is 0001595248 (1595248). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Genprex, Inc.'s SEC filings?
All of Genprex, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.